Last reviewed · How we verify
Vaxxinity, Inc. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
0 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| BNT162b2 vaccine | BNT162b2 vaccine | marketed | Not specified | Not specified | Infectious Disease | |
| ChAdOx1-S vaccine | ChAdOx1-S vaccine | phase 3 | Viral vector vaccine | SARS-CoV-2 spike protein | Immunology / Infectious Disease | |
| Sinopharm BIBP | Sinopharm BIBP | phase 3 | Inactivated viral vaccine | SARS-CoV-2 spike protein and other viral antigens | Immunology / Infectious Disease |
Therapeutic area mix
- Immunology / Infectious Disease · 2
- Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Bharat Biotech International Limited · 2 shared drug classes
- Crucell Holland BV · 2 shared drug classes
- Pfizer · 2 shared drug classes
- CanSino Biologics Inc. · 1 shared drug class
- Boryung Pharmaceutical Co., Ltd · 1 shared drug class
- Cellid Co., Ltd. · 1 shared drug class
- Centers for Disease Control and Prevention · 1 shared drug class
- BioNTech · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Vaxxinity, Inc.:
- Vaxxinity, Inc. pipeline updates — RSS
- Vaxxinity, Inc. pipeline updates — Atom
- Vaxxinity, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Vaxxinity, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vaxxinity-inc. Accessed 2026-06-10.